Obliterative bronchiolitis (OB) refers to a rare but serious condition resulting in progressive and irreversible airway obstruction. This syndrome is the result of injury to the respiratory and terminal bronchioles from a wide variety of potential causes.1 Here, we provide a general overview of OB and then focus on the syndrome in two transplant populations where its development has major implications on long-term survival. In lung transplant recipients, bronchiolitis obliterans syndrome (BOS) is the major cause of death after the first year of transplantation and is a form of allograft rejection.2 An analogous syndrome develops in 5% to 10% of human stem cell transplant (HSCT) recipients and is associated with major morbidity and mortality.3
Much confusion exists among clinicians regarding the similar terminologies used for vastly different pulmonary conditions. The conditions most often confused are OB and an entity previously named bronchiolitis obliterans organizing pneumonia, now referred to as cryptogenic organizing pneumonia.4,5 Obliterative bronchiolitis is primarily a syndrome of progressive air trapping due to involvement of small airways without parenchymal involvement. Bronchiolitis obliterans organizing pneumonia/cryptogenic organizing pneumonia is significantly more common and manifests as parenchymal disease with alveolar consolidation and intraluminal polyps in the respiratory bronchioles.4Table 1 contrasts many of the clinical, pathologic, and radiologic characteristics of clinical syndromes, which are often confused due to their nomenclature. Much of this confusion is the result of the terms being used to denote a clinical syndrome by clinicians and as a histopathologic finding by pathologists.
The pathogenesis of OB remains poorly understood in all its manifestations. Ultimately, injury to the respiratory epithelium and subepithelium results in dysregulation of epithelial repair and development of disease. Injury results in denudation of the epithelium and loss of basilar progenitor cells.6 This is followed by an inflammatory infiltrate and the development of an abnormal cytokine response profile.7 Epithelial-mesenchymal transition may occur, resulting in excessive accumulation of fibroblasts and resultant fibroproliferation.8 Several divergent inflammatory mechanisms have been invoked in attempting to explain the disease, particularly in lung transplantation. Further, the pathways which lead to the histopathological finding of constrictive bronchiolitis, airway distortion, and subepithelial fibrosis in circumstances of toxin exposure, autoimmunity, and transplant related alloimmunity may share some immunological commonality. In one model of rodent diacetyl exposure, the posited mechanism involved damage to membrane proteins which compromised epithelial integrity and led to migration of fibroblast precursors from the ulcerated airway wall into the lumen.9 This process of trigger leading to epithelial injury with resultant inflammation and fibroproliferation is thought to underpin the development of OB in all its forms, though a comprehensive step-by-step sequence has yet to be clearly elucidated.
Exposure to diacetyl, a key component of artificial butter flavoring, has been associated with an increased risk of developing OB in workers at a microwave-popcorn production plant.10 Indeed, diacetyl exposure has been shown in a murine model to result in the development of epithelial injury, peribronchial lymphocytic inflammation, and fibrohistiocytic lesions in the terminal bronchioles in a manner consistent with OB.11
Similarly, exposure to 2,3-pentanedione (an alternative component of artificial butter flavoring) is associated with airway epithelial toxicity and histopathological changes similar to OB.12 After exposure to this compound in a rat model, analysis of fibrotic airways showed significant up-regulation of transforming growth factor-β (TGF-β) and downstream genes implicated in fibrosis. Further, genes coding for peptidases and peptidase inhibitors were significantly altered, demonstrating changes consistent with airway remodeling.13 In in vitro models of mechanical airway injury, TGF-β has been shown to increase in a dose-dependent fashion and enhance downstream modulators of fibrosis.14 These data support the notion that nontransplant OB is mediated through common fibrotic pathways.
The clinical impact of BOS, established above, has prompted a substantial amount of effort to identify the molecular underpinnings of disease in an attempt to develop effective therapy. As a result, this represents the best understanding of the pathophysiology of OB-spectrum diseases. Here, we will attempt to describe a variety of key inflammatory pathways to introduce the modern understanding of disease development.
In an extrapolation of the findings illustrated in OB, blood samples were obtained from 51 lung transplant recipients to assess for serologic evidence of altered fibrotic pathways. Indeed, patients with clinical evidence of BOS have more circulating fibrocytes and fewer circulating epithelial progenitors when compared to those without evidence of disease.15,16 Further, BOS has been associated in multiple studies with bronchial epithelial to mesenchymal transition (EMT), a process that has been shown to be accentuated both by TGF-β and by modulators of TGF-β activity.17-19 For example, in a laboratory model of human lung epithelial injury, the coadministration of TNF-α and TGF-β significantly enhanced features of EMT and treatment of injured epithelium with TGF-β in the presence of an activated macrophage-like cell line resulted in accentuated changes in cell phenotype when compared to treatment with TGF-β alone.20
Clinically, acquisition of Pseudomonas aeruginosa has been shown to increase the risk of BOS. In primary bronchial epithelial cells collected from recipients of lung transplantation, the coculturing of Pseudomonas-activated monocytes with primary bronchial epithelial cells significantly accentuated TGF-β1–driven EMT, a finding which demonstrates that through activation of monocytic cells, Pseudomonas can affect changes in cellular fibrotic pathways.21 These findings demonstrate that complex cytokine and cellular processes upregulate the fibrotic pathways associated with BOS.
The role of lymphocytes in the development of BOS is also complex. For example, in a murine model of tracheal transplantation into mismatched mice, provision of either anti-CD4+ or anti-CD8+ antibody treatments partially reduced the histopathologic development of obstructive airways disease, whereas combined therapy against both anti-CD4+ and anti-CD8+ cells resulted in further interruption of disease development, demonstrating that both of these types of T cells have a role in the pathogenesis of obstructive airway disease.22 Similarly, in a separate model of lung transplantation using fully mismatched mice, allospecific CD8+ T cells were detected in airway allografts shortly after transplantation. Interestingly, an influx of similar CD8+ effector cells was identified in the allograft once obstructive airways disease had developed. Antibody-mediated depletion of CD8+ T cells resulted in decreased luminal obliteration and fibrosis in this setting.23
Th17 cells provide a major source of IL-17A. Upregulation of both IL-17A and Th17 cells have been associated with the development of BOS. In a murine model of lung transplantation, depletion of CD4+ T cells has been shown to lead to significantly decreased frequency of IL-17A+ lymphocytes. This was found to be protective against acute rejection and BOS.24 In contradistinction, mice with genetic deficiencies preventing differentiation of precursor cells into Th17 cells had stable IL-17A+ lymphocyte frequencies and comparable rates of rejection. This is thought to be secondary to the enhanced presence of γδ T cells.24 These data suggest that although CD4+ cells are necessary for the development of BOS, the absence of Th17 cells is not, by itself, protective. This represents a complex relationship between a variety of T lymphocytes in which the balance of each depends on the activity of the other. Similar circumstances have been described among other subsets of T lymphocytes and ongoing work continues to attempt to define this complex interplay.
Further, there is emerging recognition that regulatory T cells help maintain an immunologic homeostasis. In 1 small series, the presence of regulatory T cell–specific markers in the blood of lung transplant recipients was correlated with better lung function after transplantation.25 Although few clinical studies have used the awareness of regulatory T cells, it is known that depletion of this cell type results in counterproductive effects of some transplant immunotherapy.26
Antibodies to graft antigens are strongly linked to the development of BOS in lung transplantation. In several reviews, HLA locus mismatch and development of donor-specific anti-HLA antibodies (DSA) have been described as significant independent predictors of the development of BOS after lung transplantation.27-31 Further, both decreased incidence of BOS and increased survival have been associated with clearance of DSA.32 These data suggest a role for the presence of DSA in the development of the chronic inflammatory state which precedes BOS.
Although antibody-mediated rejection (AMR) of lung allografts has long been suspected, proving its existence has been relatively complex. Recently, a series of 21 patients with clinical and histological evidence of acute antibody-mediated lung allograft rejection was described. Each of these patients had identification of DSA, and the simultaneous demonstration of endothelial deposition of the complement split product C4d on transbronchial lung biopsy. Fifteen of these patients survived the incident hospitalization associated with the AMR episode, one of whom had previously been diagnosed with BOS. Of the 14 patients without previously identified BOS, AMR was associated with the development of subsequent chronic allograft dysfunction in 13 patients.33
In recent years, there has been emerging recognition of the role of autoimmunity in the development of chronic allograft dysfunction. Processes associated with allograft injury may lead to exposure of intercalated self-antigens which lead to cellular and antibody-mediated immune responses.7 In lung tissue, this pattern has been associated with collagen V and k-α 1 tubulin. Presence of antibodies against these epithelial cell antigens has been associated with the development of BOS.34 Identification of DSA precedes development of these antiepithelial antibodies, and their presence increases the risk of BOS after transplantation.35,36
In this section, we have attempted to delineate some of the suspected mechanisms of OB-spectrum disease development. Epithelial injury is thought to expose targets for humoral, cellular, and innate immunologic activation. This injury may take the form of infectious or environmental damage, though other mechanisms (such as ischemia-reperfusion injury after lung transplantation) likely contribute. Antibody and lymphocyte mediated immune responses initiate damage and fibrotic pathways (including EMT) are activated. It is nearly certain that these responses are intertwined, though the details of their relationship are, as yet, incompletely defined. Regardless, it seems clear that a multifaceted process of inflammation and resultant fibrotic transition occurs, resulting in airflow limitation and development of disease. Although much of the pathophysiologic knowledge arises from lung transplant pathology, the overlap between disease in nontransplant, solid organ transplant and HSCT settings is unclear. Some pathophysiologic links exist but further work is needed to clarify the relationship.
Table 2 summarizes the many possible causes of OB. This is an important and underrecognized disease in the general pulmonary population. Disease may follow infectious, pharmacologic, and environmental exposures as well as autoimmune disease, such as rheumatoid arthritis. Clinically, most patients present with progressive dyspnea and cough, which are often misdiagnosed as asthma or emphysema. There is frequent progression to significant debility before the correct diagnosis is achieved.
Most commonly, chest radiographs in OB are relatively normal though hyperinflation and peripheral attenuation of vascular markings may become obvious in advanced disease. High-resolution CT scanning, preferably with inspiratory and expiratory views, reveals mildly dilated airways, thickened bronchial walls and signs of patchy air trapping which manifest as a pattern of mosaic attenuation (areas of hyperlucent lung alternating with areas of increased lung density).37
Obliterative bronchiolitis is also suggested by the absence of associated ground glass opacities (commonly seen in hypersensitivity pneumonitis), the absence of tree-in-bud opacities (commonly seen in infectious bronchiolitis) and the absence of centrilobular nodules (commonly seen in respiratory bronchiolitis interstitial lung disease).
Pulmonary Function Testing
Spirometry in OB typically demonstrates an obstructive ventilatory defect with a progressive decline in the forced expiratory volume over 1 second (FEV1) and a decrease in the ratio of FEV1 to forced vital capacity (FVC).37-39 In addition, decline in small airways forced expiratory flow (FEF25–75) occurs and may be an early indicator of developing airflow obstruction. Response to inhaled bronchodilators is generally poor but some patients may have mild spirometric improvement. Body plethysmography reveals air trapping and elevated residual volume. Diffusing capacity for carbon monoxide is typically reduced in advanced disease although it may remain normal in the early stages of illness. Impairment of gas exchange and hypoxemia, initially with exertion and then at rest, occur as the obstructive ventilatory defect worsens.
Obliterative bronchiolitis can be classified as either “constrictive,” representing circumferential fibrosis compressing the bronchiolar lumen, or “proliferative,” representing histologic proliferation of fibroelastic polypoid tissue in the bronchiolar lumen. In constrictive disease, histologic evaluation demonstrates peribronchiolar cellular infiltrates which progress to airway distortion and ultimately subepithelial fibrosis. Trichrome staining identifies fibrosis in bronchiolar muscle.40,41 In proliferative disease, an intraluminal bud called a “Masson body” fills the airway lumen, leading to bronchiolar plugging and extension through the conducting airways.4 A butterfly wing-like appearance may be microscopically observed.42 Organizing pneumonia is more commonly associated with proliferative disease. Table 1 reviews the histopathologic differences between OB and related diagnoses.
Obliterative lesions are localized from the small bronchi to membranous bronchiole. Intermittent distribution is seen in constrictive disease, whereas destructive/proliferative disease is associated with continuous obliteration of the bronchiolar lumen.43-45 The diagnosis is usually made based on clinical findings, imaging, and pulmonary function testing with a rare need for histologic evidence of disease. Owing to lesion heterogeneity and distribution, surgical lung biopsy is superior to transbronchial approaches in the rare circumstances, where there is sufficient diagnostic uncertainty to warrant biopsy.
There is no uniformly accepted treatment protocol for patients with OB. Many patients are tried on corticosteroids or other immunosuppressants based on anecdotal evidence of improvement.38 These medications have significant toxicity and may complicate optimization for lung transplantation. Macrolides have been used with some success in lung transplant-related BOS which results in some use in OB, though evidence for this practice is scant. Routine vaccination against pneumococcus and influenza are recommended as in other chronic lung diseases.
Although some patients stabilize after an initial decline, disease typically progresses to respiratory failure with or without cor pulmonale. Patients with hypoxemia should be treated with oxygen. As the obstructive defect progresses, gram-negative airway colonization may occur, resulting in complex antimicrobial management needs. Ultimately, many patients require transplantation, which remains the ultimate treatment for OB in appropriate patients.46
After lung transplantation, the term BOS describes a late complication involving persistent decline in spirometrically measured FEV1 that is not associated with another known and potentially reversible cause of allograft dysfunction. This phenomenon shares some histopathological overlap with OB and affects up to 50% of lung transplant recipients who survive at least 5 years after transplantation, making it the most commonly recognized noninfectious form of chronic lung allograft dysfunction (CLAD). It has a highly variable clinical course and is the leading cause of death beyond the first posttransplant year, responsible for 40% of deaths after lung transplantation.7,46,47 Survival is worse in patients who develop early-onset BOS or have higher grades at disease onset.2,7 Median survival after BOS diagnosis has been reported as 2.5 years with a 74% mortality within 5 years of diagnosis.31
Bronchiolitis obliterans syndrome was initially described in 1984 when a number of early heart-lung transplant recipients were noted to have developed airway disease 3 years after transplantation. Pathological evaluation of these allografts revealed OB.48 In 1993, the International Society for Heart and Lung Transplantation (ISHLT) published the results of a working group on CLAD. This group formally standardized the term BOS and established a severity grading system based on the FEV1.49
In 2002, the ISHLT released a new consensus on the definition of BOS designed to improve sensitivity to early changes in lung function, which represent potential targets for intervention. To accomplish this, subtle changes in FEV1 were separated out, and the FEF25–75 was incorporated to identify a “possible BOS” classification. The “baseline” FEV1 was defined as the average of the 2 highest posttransplant measurements obtained on separate visits at least 3 weeks apart. Bronchiolitis obliterans syndrome was divided into 4 subclasses which were defined as follows: BOS 0 represented an FEV1 greater than 90% of baseline and FEF25–75 greater than 75% of baseline; BOS 0-p represented an FEV1 of 81% to 90% of baseline and/or FEF25–75 75% or less of baseline; BOS 1 represented an FEV1 of 66% to 80% of baseline; BOS 2 represented an FEV1 of 51% to 65% of baseline; and BOS 3 represented an FEV1 of 50% or less of baseline.50 Importantly, other identifiable causes of allograft dysfunction (acute respiratory infection, and so on) should be excluded before the diagnosis of BOS can be made. This scheme continues to be the classification system used to describe the degree of allograft dysfunction present in the period after lung transplantation.
Intrinsic Risk Factors
Early studies have established a relationship between the presence of recipient genetic polymorphisms and the risk of BOS. Identified mutations involve a wide array of functions, ranging from toll-like receptors to cytokine regulators and innate immune responses. The strength and causality of these genetic relationships is poorly established and remains an area of active research.51
Numerous cellular and cytokine-related factors have been identified as predictors of BOS. For example, the presence of greater degrees of neutrophilia in bronchoalveolar lavage (BAL) fluid has been associated with a marked increase in the risk of developing BOS.52 In another study, increased serum levels of KL-6 (a MUC1 mucin which is sensitive for inflammatory pulmonary disorders) were shown to significantly correlate with decline in FEV1 after lung transplantation.53 Continued investigations into possible predictive factors will be necessary to attempt earlier identification and treatment of at-risk patients.
Primary graft dysfunction after lung transplantation represents the development of acute lung injury in the immediate posttransplant period. The mechanism of this disease is thought to be a nonimmune development of ischemia-reperfusion injury associated with the mechanical procedure of transplantation. Indeed, this phenomenon has been observed in canine autotransplantation, even in the setting of technically uncomplicated surgery.54,55 Primary graft dysfunction of all levels of severity has been associated with a significantly increased risk of BOS in a manner independent of other risk factors.56 The mechanism for this association is imperfectly understood but may represent the relationship between allograft injury, antigen exposure and inflammatory response described above.
Episodes of acute cellular rejection have consistently been identified as the strongest risk factors for the development of BOS.2,57-59 Conventionally, cellular rejection is identified by perivascular lymphocytic infiltrates on histopathologic examination. However, peribronchiolar lymphocytic infiltrates are also seen in some cases of acute cellular rejection. In recipients of lung transplantation, there is an increased risk of BOS associated with higher grades of lymphocytic bronchiolitis.60,61 The relationship between acute rejection and the development of BOS, however, is not limited to severe rejection episodes. In a series of 228 lung transplant recipients, an episode of “minimal acute cellular rejection” (the lowest severity of biopsy-proven rejection) persisted as a distinct risk factor for BOS even when controlled for other known risk factors.62
Gastroesophageal reflux has long been associated with various forms of lung disease presumably through reflux mediated injury. This association extends to BOS in recipients of lung transplantation, leading some centers to aggressively treat evidence of reflux with pharmacological and surgical measures.2,63 Among lung transplant recipients with pH probe-diagnosed gastroesophageal reflux, annual decline in FEV1 was noted to be significantly worse than controls, although those who received surgical fundoplication had clinically and statistically significant improvements in peak FEV1 up to 1 year after surgery when compared to those who did not.64
Microbiological and Environmental Factors
Tissue damage and antigenic exposure, thought to be participatory in the development of BOS, is commonly associated with infection. Cytomegalovirus (CMV) has been strongly associated with development of BOS after lung transplantation.7,65,66 Among 231 lung transplant recipients, 21% of patients had evidence of CMV pneumonitis within 6 months of transplant. This finding was strongly associated with a higher incidence of BOS and posttransplant death and persisted despite treatment with ganciclovir.66 This has led to widespread use of early CMV prophylaxis and aggressive treatment of CMV viremia after lung transplantation. Indeed, extension of prophylaxis through a decrement in prednisone dose to less than 0.1 mg/kg per day has been associated with decreased incidence of both CMV complications and BOS after lung transplantation.67
Both cumulative exposure to aerosolized particulate matter (pollution) and proximity of a patient's home to major roadways have been significantly associated with development of BOS.68,69 Additionally, community-acquired respiratory viruses have been associated with an increased risk of BOS. Acquisition of a community acquired respiratory virus has been associated with both a significant increase of developing advanced BOS and a worsened mortality.70,71 Many patients who undergo lung transplantation (such as those with cystic fibrosis) have colonization of their native lungs with pathogenic microorganisms. After transplantation, these organisms can recolonize the lower airways of the allograft, a phenomenon that is associated with increased incidence of BOS.63,72 Together, these findings suggest microbiological and environmental factors may increase risk of BOS development.
Treatment—Steroids and Standard Immunosuppression
Considering the complex immunologic processes involved in the development of BOS, it is unsurprising that no specific therapeutic approach has been uniformly adopted as a “standard of care.” Although the optimal immunosuppression regimen after transplantation is uncertain, lower cumulative exposure to immunosuppressant drugs is associated with increased incidence of BOS.7,60,73 Therefore, careful attention to maintenance immunosuppression is a key component of prevention.
The role of induction immunosuppression is unclear. In an analysis of the United Network for Organ Sharing database, induction immunosuppression was associated with improved graft and patient outcomes for kidney, liver, and lung transplantation.74 Induction immunosuppression carries increased risks of infection and has the potential to increase the risk of malignancies associated with immunosuppression. Further, other analyses of lung transplant recipients have failed to demonstrate strong survival benefits associated with this therapy.57 As a result, significant variability in lung transplant center induction practice exists, and overall use of induction immunosuppression has significantly decreased in recent years.75
The 2014 ISHLT/European Respiratory Society consensus guidelines on the management of BOS list augmentation of immunosuppression (styled as a 3-day course of daily doses of 1000 mg of intravenous methylprednisolone) as a primary approach to rejection episodes, including minimal acute cellular rejection. Although there is a clear relationship between rejection episodes and the development of BOS, the evidence supporting the use of high doses of steroids to abrogate this association is weak. Therefore, this recommendation comes with the recognition that short time side effects may increase but justifies tolerance of this reality through the hope of decreasing the likelihood of life-threatening allograft rejection. High doses of corticosteroids, however, are not recommended for the long-term management of BOS given the poor evidence and the more significant potential deleterious effects associated with prolonged use.47
Retrospective data have demonstrated significant improvements in FEV1 after initiation of macrolide antibiotics, particularly among patients with a high degree of neutrophilia in BAL fluid.76,77 In a separate study, azithromycin administration was associated with a survival advantage in patients with BOS and demonstrated a more pronounced effect when treatment was initiated during BOS stage 1.78 In a double-blind, randomized, controlled trial of azithromycin for the prevention of BOS, administration of 250 mg of azithromycin thrice weekly was associated with significant improvements in BOS-free survival with improved FEV1 and decreased airway neutrophilia.79 The proper duration of therapy is not established and provides an area of necessary further investigation. In a pilot study of the use of montelukast in BOS, patients started on treatment immediately after diagnosis experienced a significantly reduced rate of decline in lung function as compared to a retrospectively selected control cohort.80 This represents another potential therapeutic intervention for BOS and warrants larger-scale analyses.
Pirfenidone, an inhibitor of fibroblast proliferation, has been recently approved for the treatment of idiopathic pulmonary fibrosis in the United States. In a rodent model of tracheal transplantation, administration of pirfenidone was associated with less epithelial cell injury and less luminal fibrosis when compared with untreated controls. Of note, pirfenidone treated animals also exhibited decreased plasma TGF-β levels and local TGF-β expression based on immunhistochemistry.81
Extracorporeal photophoresis (ECP) involves the procedure of removing a portion of the patient's blood volume from which the leukocyte-enriched buffy coat is extracted and exposed to ultraviolet light in the presence of 8-methoxypsoralen. This leads to binding of DNA, cell-surface molecules and cytoplasmic components in exposed leukocytes and results in leukocyte dysfunction. Although further evidence is needed, this therapy has been associated with a reduction in the rate of decline in lung function in patients with BOS after lung transplantation, a response that may be variable depending on the phenotype of the patient's allograft dysfunction.82-84
Radiation induced lymphocyte depletion (in the form of total lymphoid irradiation [TLI]) was used in Hodgkin lymphoma before cytotoxic chemotherapy became widely available. This therapy has also been utilized to induce t-cell depletion and immunosuppression in solid organ transplant recipients.85 In the largest series, examining the use of TLI in 37 patients with BOS, therapy was both well tolerated and associated with significant improvements in the rate of decline in FEV1.86 Given the relative paucity of data regarding TLI, further studies will be useful in defining the proprietary role of this treatment in the prevention of CLAD.
Finally, in the absence of effective relief of BOS, patients should be referred for consideration of retransplantation. Retransplantation represents a complex, controversial intervention with poor outcomes and high cost. Although outcomes still lag behind recipients of initial transplants, they have improved. Among 205 recipients of retransplantation between 2001 and 2006, the risk of death was significantly lower than it had been among patients retransplanted between 1990 and 2000. However, the risk of death was significantly higher than that experienced among patients undergoing initial transplant during the more modern period.87 Therefore, consideration of retransplantation should be undertaken in a multidisciplinary fashion with a careful consideration of patient-specific factors likely to affect outcome.
Phenotypes of CLAD
Because the primary focus of this article is the spectrum of diseases associated with the histopathologic appearance of OB, BOS has been discussed at greatest length. It is important to recognize, however, that other forms of CLAD have been described. The restrictive allograft syndrome has been recently described as a progressive decline in lung function with proportional decreases in both FVC and FEV1.88 Allograft biopsy demonstrates pleuroparenchymal fibroelastosis with or without diffuse alveolar damage, though several patients also had lesions consistent with concomitant OB.89 Disease progression follows a “stair step” pattern with frequent exacerbations and intermittent stability, though survival associated with this syndrome is worse than that observed in patients with BOS.88,90 Although little is known about the underlying pathophysiology of, or risk factors for, this disease, the same pathologic findings have been found in a small number of patients after hematopoietic stem cell transplantation and in a number of patients for whom no cause was identified.91
Other phenotypic questions which remain unanswered include the pathophysiologic differences between disease in patients with rapidly progressive courses as compared to those with more gradual declines in lung function. The BAL neutrophilia has been demonstrated to be variably present in BOS and represents a circumstance which predicts better responses to certain therapeutic interventions.76,77,84
HEMATOPOIETIC STEM CELL TRANSPLANT
Hematopoietic stem cell transplant is an increasingly utilized treatment for hematologic malignancies, aplastic anemia, and rare immunodeficiency disorders, offering approximately half of all recipients' long-term disease-free survival.92,93 The high rate of transplant-related mortality initially limited use of this intervention; however, evolution of transplant medicine over the past 3 decades has significantly reduced the short-term mortality, allowing more patients to live long enough to experience late complications.94 Chronic graft-versus-host disease (cGVHD) is the most common late complication of HSCT and is manifested in the lungs as BOS in a manner clinically and pathologically similar to that seen in the BOS phenotype of CLAD, described above.
Bronchiolitis obliterans syndrome occurs in 2% to 4% of all HSCT recipients.95 Greater than 80% of cases of BOS after HSCT occur within 18 months of transplant, and 5-year survival among affected patients may be as low as 10%.95-100
In 2005, a National Institutes of Health-sponsored consensus committee proposed a unified set of diagnostic criteria for BOS to include either biopsy proven disease or GVHD in 1 organ other than the lung plus all of the following: FEV1/FVC ratio less than 0.7 with FEV1 less than 75% predicted; evidence of air trapping, airway thickening, or bronchiectasis on high-resolution CT or residual volume greater than 120%, and absence of infection in the respiratory tract.101
Development of cGVHD in an extrapulmonary site is a significant risk for BOS with a more than two-fold increase in incidence when extrapulmonary involvement is identified. Up to 97% of patients with BOS have identifiable disease in other organs.92,97 Additionally, acute GVHD portends a high risk for subsequent development of chronic disease.96,99,102
Before HSCT, all patients undergo a conditioning regimen of myeloablative chemotherapy to create a hospitable bone marrow environment for engraftment. As many chemotherapeutic agents carry significant risk of adverse pulmonary effects, the regimen selected for this purpose poses a risk for the development of subsequent disease. Specifically, in several series, busulfan-based regimens have been associated with the development of BOS after HSCT.102-104 This effect may be the result of direct epithelial toxicity causing antigenic exposure and subsequent donor alloreactivity. In contradistinction, the use of antithymocyte globulin as part of the conditioning regimen has been demonstrated to be protective against the development of BOS.102
After conditioning, patients are infused with donor cells. These cells were conventionally acquired directly from bone marrow, although pheresis-driven acquisition of peripheral blood stem cells has become increasingly common. Use of peripheral blood stem cell has been identified as an independent risk factor for BOS (95, 102, 105).
Unsurprisingly, the degree of mismatch between donor and recipient does appear to play a significant role, with a higher BOS rate at 2 years among recipients from a matched-unrelated or mismatched donor (40%) than those with a matched-related donor (20%).105 This relationship persists regardless of the method of stem cell acquisition.105 In conjunction with the multiple reports of a decreased incidence of BOS in patients who receive T cell–depleted transplants, this suggests a strong role for alloantigen recognition in HSCT-associated complications.106-108
Female sex of both recipient and donor has been shown across multiple studies to confer a significant risk for BOS.92,95,96,102,104 The putative mechanism for this may involve endocrinologic factors or the complex immunological effect of conception and pregnancy, although it remains poorly understood. Patients younger than 20 years, those with an abnormal FEV1 before transplantation, those who develop respiratory infections within the first 100 days after transplant and those with an ABO-incompatible donor all have a higher risk for developing BOS as well.99,102,104
Treatment—Steroids and Standard Immunosuppression
Unfortunately, the treatment of long-term pulmonary complications in HSCT has lagged behind advances in transplant protocols. There are currently no randomized trials evaluating optimal treatments for BOS, and treatment is based largely on data from small cohorts and retrospective clinical trials.
Post-HSCT prophylaxis for GVHD is a complex topic with relatively poor standardization. In a large meta-analysis, regimens containing tacrolimus or antithymocyte globulin in combination with methotrexate and/or cyclosporine were associated with decreased incidence of BOS when compared to methotrexate or cyclosporine monotherapy.109 Few studies have evaluated the role of mycophenolate or sirolimus-containing regimens.
Both the American Society for Bone Marrow Transplant and the British Society for Bone Marrow Transplant recommend corticosteroids as first line treatment for cGVHD at a dose of 1 mg/kg per day alone or in combination with a calcineurin inhibitor.110-112 There is no standardized approach to steroid taper. The expected response to first line treatments ranges from 20% to 40%, and clinical improvement after first line treatment is associated with significant improvements in survival.99,112
The combination of budesonide/formoterol inhalational therapy has been associated with a significant improvement in FEV1 sustained over 1 year after treatment initiation.113 Azithromycin, used with the above-noted success after lung transplantation, has not been clearly demonstrated to confer the same benefit after HSCT although its relatively favorable side effect profile and efficacy in other circumstances promotes its continued use in this setting.114,115 The combined use of the inhaled corticosteroid fluticasone, the macrolide azithromycin, and the leukotriene inhibitor montelukast was associated with more rapid weaning from systemic corticosteroids despite preservation of FEV1 in a small, retrospective, case-control study.116
The TNF-α inhibitor etanercept and ECP have both been demonstrated to have some success in achieving systemic corticosteroid reduction and disease stabilization, although these are considered second-line therapy in most centers.117-123
Identification of antibodies activating the platelet-derived growth factor receptor pathway led to the use of the tyrosine kinase inhibitor imatinib in a small study of patients with treatment refractory, fibrotic GVHD. Six months after treatment initiation, 15 of 19 patients had achieved either complete or partial remission, a response that persisted in 14 of those patients through 17 months of follow-up.124 Multiple other immunomodulators, including rituximab and thalidomide, have been studied in BOS with disappointing results.125-127
As in lung transplantation, ECP has been tried in the therapy of GVHD after HSCT. In 1 study of 95 patients, those randomized to ECP experienced a significant increase in the likelihood of decrease in steroid dose as well as a decrease in cutaneous involvement of disease.119 It is not clear whether these findings extend to improvement in pulmonary function, and further studies are necessary to clarify the role of ECP in BOS after HSCT.
Finally, in patients with advanced BOS, lung transplantation may be considered as a therapeutic option. This has been controversial owing to the presence of recent malignancy as a relative contraindication to lung transplantation. Further, there is concern that the immunologic processes underlying the development of BOS after HSCT may be equally pathological and poorly responsive after lung transplantation. In 1 series of 7 patients who underwent lung transplant a median of 18 months after the diagnosis of BOS, median survival was 24 months, significantly less than that reported among the general population of lung transplant recipients.128 In a more recent review of the reported literature, 84 recipients of lung transplantation after HSCT were described by Soubani et al.129 The median time between HSCT and lung transplant was 52 months. Three years after lung transplantation, survival was 71% with 30% of patients developing BOS and only 2 patients experienced a relapse of their hematologic malignancy. This suggests better outcomes than initially reported and raises the prospect of lung transplantation as a means to improve outcomes in appropriately selected patients with advanced BOS after HSCT.
Obliterative bronchiolitis is likely the pathologic consequence of a series of elaborate immunological and nonimmunological processes. This disease is the complex result of a poorly understood progression toward airway epithelial dysfunction. Obliterative bronchiolitis in nontransplant populations may be the result of autoimmune disease or inhalational exposure but an etiologic agent is not always determined. A spectrum of related disease plays a significant role in the outcomes of patients who undergo lung transplantation and hematopoietic stem cell transplantation. Regardless of the cause, this pathology is associated with significant disease burden and poor responsiveness to treatment. Ongoing investigations are necessary to help elucidate the best approach to preventing this epithelial dysfunction and improving the lives of affected patients.
1. Wright JL, Cagle P, Churg A, et al. Diseases of the small airways. Am Rev Respir Dis
. 1992; 146: 240–262.
2. Hachem RR, Trulock EP. Bonchiolitis obliterans syndrome: pathogenesis and management. Semin Thorac Cardiovasc Surg
. 2004; 16: 350–355.
3. Yen KT, Lee As, Krowka MJ, et al. Pulmonary complications in bone marrow transplantation: a practical approach to diagnosis and treatment. Clin Chest Med
. 2004; 25: 189–201.
4. Epler GR, Colby MD, Thomas V, et al. Bronchiolitis obliterans organizing pneumonia. N Engl J Med
. 1985; 312: 152–158.
5. Barker AF, Bergeron A, Rom WN, et al. Obliterative bronchiolitis. N Engl J Med
. 2014; 370: 1820–1828.
6. O’Koren EG, Hogan BL, Gunn MD. Loss of basal cells precedes bronchiolitis obliterans-like pathological changes in a murine model of chlorine gas inhalation. Am J Respir Cell Mol Biol
. 2013; 49: 788–797.
7. Weigt SS, DerHovanessian A, Wallace WD, et al. Bronchiolitis obliterans syndrome: the Achilles' heel of lung transplantation. Semin Respir Crit Care Med
. 2013; 34: 336–351.
8. Pain M, Bermudez O, Lacoste P, et al. Tissue remodelling in chronic bronchial diseases: from the epithelial to mesenchymal phenotype. Eur Respir Rev
. 2014; 23: 118–130.
9. Palmer SM, Flake GP, Kelly FL, et al. Severe airway epithelial injury, aberrant repair and bronchiolitis obliterans develops after diacetyl instillation in rats. PLoS One
. 2011; 6: e17644.
10. Kreiss K, Gomaa A, Kullmann G, et al. Clinical bronchiolitis obliterans in workers at a microwave-popcorn plant. N Engl J Med
. 2002; 347: 330–338.
11. Morgan DL, Flake GP, Kirby PJ, et al. Respiratory toxicity of diacetyl in C57BL/6 mice. Toxicol Sci
. 2008; 103: 169–180.
12. Morgan DL, Jokinen MP, Price HC, et al. Bronchial and bronchiolar fibrosis in rats exposed to 2,3-pentanedione vapors: implications for bronchiolitis obliterans in humans. Toxicol Pathol
. 2012; 40: 448–465.
13. Morgan DL, Merrick BA, Gerrish KE, et al. Gene expression in obliterative bronchiolitis-like lesions in 2,3-pentanedione-exposed rats. PLoS One
. 2015; 10: e0118459.
14. Thompson HG, Mih JD, Krasieva TB, et al. Epithelial-derived TGF-beta2 modulates basal and wound-healing subepithelial matrix homeostasis. Am J Physiol Lung Cell Mol Physiol
. 2006; 291: L1277–L1285.
15. Gilpin SE, Lung KC, Sato M, et al. Altered progenitor cell and cytokine profiles in bronchiolitis obliterans syndrome. J Heart Lung Transplant
. 2012; 31: 222–228.
16. Lapar DJ, Burdick MD, Emaminia A, et al. Circulating fibrocytes correlate with bronchiolitis obliterans syndrome development after lung transplantation: a novel clinical biomarker. Ann Thorac Surg
. 2011; 92: 470–477.
17. Borthwick LA, Parker SM, Brougham KA, et al. Epithelial to mesenchymal transition (EMT) and airway remodeling after human lung transplantation. Thorax
. 2009; 64: 770–777.
18. Hodge S, Holmes M, Banerjee B, et al. Posttransplant bronchiolitis obliterans syndrome is associated with bronchial epithelial to mesenchymal transition. Am J Transplant
. 2009; 9: 727–733.
19. Liu X. Inflammatory cytokines augments TGF-beta1-induced epithelial-mesenchymal transition in A549 cells by up-regulating TbetaR-I. Cell Motil Cytoskeleton
. 2008; 65: 935–944.
20. Borthwick LA, McIlroy EI, Gorowiec MR, et al. Inflammation and epithelial to mesenchymal transition in lung transplant recipients: role in dysregulated epithelial wound repair. Am J Transplant
. 2010; 10: 498–509.
21. Borthwick LA, Sunny SS, Oliphant V, et al. Pseudomonas aeruginosa accentuates epithelial-to-mesenchymal transition in the airway. Eur Respir J
. 2011; 37: 1237–1247.
22. Higuchi T, Jarmaillo A, Kaleem Z, et al. Different kinetics of obliterative airway disease development in heterotopic murine tracheal allografts induced by cd4+ and cd8+ t cells. Transplantation
. 2002; 74: 646–651.
23. West EE, Lavoie TL, Orens JB, et al. Pluripotent allospecific CD8+ effector t cells traffic to lung in murine obliterative airway disease. Am J Respir Cell Mol Biol
. 2006; 34: 108–118.
24. Wu Q, Gupta PK, Suzuki H, et al. CD4 T cells but not TH17 cells are required for mouse lung transplant obliterative bronchiolitis. Am J Transplant
. 2015; 15: 1793–1804.
25. Nakagiri T, Warneke G, Avsar M, et al. Lung function early after lung transplantation is correlated with the frequency of regulatory t cells. Surg Today
. 2012; 42: 250–258.
26. Neujahr DC, Larsen CP. Regulatory T cells in lung transplantation—an emerging concept. Semin Immunopathol
. 2011; 33: 117–127.
27. Smith MA, Sundaresan S, Mohanakumar T, et al. Effect of development of antibodies to HLA and cytomegalovirus mismatch on lung transplantation survival and development of bronchiolitis obliterans syndrome. J Thoracic Cardiovasc Surg
. 1998; 116: 812–820.
28. Chalermskulrat W, Neuringer IP, Schmitz JL, et al. Human leukocyte antigen mismatches predispose to the severity of bronchiolitis obliterans syndrome after lung transplantation. Chest
. 2003; 123: 1825–1831.
29. Girnita AL, Duquesnoy R, Yousem SA, et al. HLA-specific antibodies are risk factors for lymphocytic bronchiolitis and chronic lung allograft dysfunction. Am J Transplant
. 2005; 5: 131–138.
30. Palmer SM, Davis RD, Hadjiliadis D, et al. Development of an antibody specific to major histocompatibility antigens detectable by flow cytometry after lung transplant is associated with bronchiolitis obliterans syndrome. Transplantation
. 2002; 74: 799–804.
31. Finlen Copeland CA, Snyder LD, Zaas DW, et al. Survival after bronchiolitis obliterans syndrome among bilateral lung transplant recipients. Am J Respir Crit Care Med
. 2010; 182: 784–789.
32. Hachem RR, Yusen RD, Meyers BF, et al. Anti-human leukocyte antigen antibodies and preemptive antibody-directed therapy after lung transplantation. J Heart Lung Transplant
. 2010; 29: 973–980.
33. Witt CA, Gaut JP, Yusen RD, et al. Acute antibody-mediated rejection after lung transplantation. J Heart Lung Transplant
. 2013; 32: 1034–1040.
34. Goers TA, Ramachandran S, Aloush A, et al. De novo production of K-alpha1 tubulin-specific antibodies: role in chronic lung allograft rejection. J Immunol
. 2008; 180: 4487–4494.
35. Salini D, Weber J, Ramachandran S, et al. Alloimmunity-induced autoimmunity as a potential mechanism in the pathogenesis of chronic rejection of human lung allografts. J Heart Lung Transplant
. 2011; 30: 624–631.
36. Triveedhi V, Gautam B, Sarma NJ, et al. Pre-transplant antibodies to Kα1 tubulin and collagen-V in lung transplantation: clinical correlations. J Heart Lung Transplant
. 2013; 32: 807–814.
37. Devakonda A, Raoof S, Sung A, et al. Bronchiolar disorders: a clinical-radiological diagnostic algorithm. Chest
. 2010; 137: 938–951.
38. Lynch JP, Weigt SS, DerHovanessian A, et al. Obliterative (constrictive) bronchiolitis. Semin Respir Crit Care Med
. 2012; 33: 509–532.
39. Turton CW, Williams G, Green M. Cryptogenic obliterative bronchiolitis in adults. Thorax
. 1981; 36: 805–810.
40. Couture C, Colby TV. Histopathology of bronchiolar disorders. Semin Respir Crit Care Med
. 2003; 24: 489–10.
41. Cagle PT. Constrictive Bronchiolitis. In Cagle PT, ed. Color Atlas and Text of Pulmonary Pathology
. 2nd ed. Philadelphia, PA: Lippincott, Williams and Wilkins; 2008: 312.
42. Cagle PT. Organizing Pneumonia (Bronchiolitis Obliterans Organizing Pneumonia). In Cagle PT, ed. Color Atlas and Text of Pulmonary Pathology
. 2nd ed. Philadelphia, PA: Lippincott, Williams and Wilkins; 2008; 309.
43. Sugino K, Hebisawa A, Uekusa T, et al. Histopathological bronchial reconstruction of human bronchiolitis obliterans. Pathol Int
. 2011; 61: 192–201.
44. Colombat M, Holifanjanianina S, Hirschi S, et al. Histologic reconstruction of bronchiolar lesions in lung transplant patients with bronchiolitis obliterans syndrome. Am J Surg Pathol
. 2014; 38: 1157–1158.
45. Verleden SE, Vasilescu DM, Willems S, et al. The site and nature of airway obstruction after lung transplantation. Am J Respir Crit Care Med
. 2014; 189: 292–300.
46. Yusen RD, Edwards LB, Kucheryavaya AY, et al. The registry of the international society for heart and lung transplantation: thirty-first adult lung and heart-lung transplant report—2014; focus theme: retransplantation. J Heart Lung Transplant
. 2014–1024; 33: 1009–1024.
47. Meyer KC, Raghu G, Verleden GM, et al. An international ISHLT/ATS/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome. Eur Respir J
. 2014; 44: 1479–1503.
48. Burke CM, Theodore J, Dawkins KD, et al. Post-transplant obliterative bronchiolitis and other late lung sequelae in human heart-lung transplantation. Chest
. 1984; 86: 824–829.
49. Cooper JD, Billingham M, Egan T, et al. A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts. J Heart Lung Transplant
. 1993; 12: 713–716.
50. Estenne M, Maurer JR, Boehler A, et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant
. 2002; 21: 297–310.
51. Kastelijn EA, van Moorsel CH, Ruven HJ, et al. Genetic polymorphisms and bronchiolitis obliterans syndrome after lung transplantation: promising results and recommendations for the future. Transplantation
. 2012; 93: 127–135.
52. Neurohr C, Huppmann P, Samweber B, et al. Prognostic value of bronchoalveolar lavage neutrophilia in stable lung transplant recipients. J Heart Lung Transplant
. 2009; 28: 468–474.
53. Ohshimo S, Bonella F, Sommerwerck U, et al. Comparison of serum KL-6 versus bronchoalveolar lavage neutrophilia for the diagnosis of bronchiolitis obliterans in lung transplantation. J Heart Lung Transplant
. 2011; 30: 1374–1380.
54. Siegelman SS, Sinha SBP, Veith FJ. Pulmonary reimplantation response. Ann Surg
. 1973; 177: 30–36.
55. Christie JD, Carby M, Bag R, et al. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part II: definition. A consensus statement of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant
. 2005; 24: 1454–1459.
56. Daud SA, Yusen RD, Meyers BF, et al. Impact of immediate primary lung allograft dysfunction on bronchiolitis obliterans syndrome. Am J Respir Crit Care Med
. 2007; 175: 507–513.
57. Girgis RE, Tu I, Berry GJ, et al. Risk factors for the development of obliterative bronchiolitis after lung transplantation. J Heart Lung Transplant
. 1996; 15: 1200–1208.
58. Heng D, Sharples LD, McNeil K, et al. Bronchiolitis obliterans syndrome: incidence, natural history, prognosis, and risk factors. J Heart Lung Transplant
. 1998; 17: 1255–1263.
59. Davis WA, Finlen Copeland CA, Todd JL, et al. Spirometrically significant acute rejection increases the risk for BOS and death after lung transplantation. Am J Transplant
. 2012; 12: 745–752.
60. Hussain AN, Siddiqui MT, Holmes EW, et al. Analysis of risk factors for the development of bronchiolitis obliterates syndrome. Am J Respir Crit Care Med
. 1999; 159: 829–833.
61. Glanville AR, Aboyoun CL, Havryk A, et al. Severity of lymphocytic bronchiolitis predicts long-term outcome after lung transplantation. Am J Respir Crit Care Med
. 2008; 177: 1033–1040.
62. Khalifah AP, Hachem RR, Chakinala MM, et al. Minimal acute rejection after lung transplantation: a risk for bronchiolitis obliterans syndrome. Am J Transplant
. 2005; 5: 2022–2030.
63. Weigt SS, Elashoff RM, Huang C, et al. Aspergillus colonization of the lung allograft is a risk factor for bronchiolitis obliterans syndrome. Am J Transplant
. 2009; 9: 1903–1911.
64. Hartwig MG, Anderson DJ, Onaitis MW, et al. Fundoplication after lung transplantation prevents the allograft dysfunction associated with reflux. Ann Thorac Surg
. 2011; 92: 462–468.
65. Paraskeva M, Bailey M, Levvey BJ, et al. Cytomegalovirus replication within the lung allograft is associated with bronchiolitis obliterans syndrome. Am J Transplant
. 2011; 11: 2190–2196.
66. Snyder LD, Finlen Copeland CA, et al. Cytomegalovirus pneumonitis is a risk for bronchiolitis obliterans syndrome in lung transplantation. Am J Respir Crit Care Med
. 2010; 181: 1391–1396.
67. Chmiel C, Speich R, Hofer M, et al. Ganciclovir/valganciclovir prophylaxis decreases cytomegalovirus-related events and bronchiolitis obliterans syndrome after lung transplantation. Clin Infect Dis
. 2008; 46: 831–839.
68. Bhinder S, Chen H, Sato M. Air pollution and the development of posttransplant chronic lung allograft dysfunction. Am J Transplant
. 2014; 14: 2749–2757.
69. Nawrot TS, Vos R, Jacobs L, et al. The impact of traffic air pollution on bronchiolitis obliterans syndrome and mortality after lung transplantation. Thorax
. 2011; 66: 748–754.
70. Gottlieb J, Schulz TF, Welte T, et al. Community-acquired respiratory viral infections in lung transplant recipients: a single season cohort study. Transplantation
. 2009; 87: 1530–1537.
71. Khalifah AP, Hachem RR, Chakinala MM, et al. Respiratory viral infections are a distinct risk for bronchiolitis obliterans syndrome and death. Am J Respir Crit Care Med
. 2004; 170: 181–187.
72. Botha P, Archer L, Anderson RL, et al. Pseudomonas aeruginosa colonization of the allograft after lung transplantation and the risk of bronchiolitis obliterans syndrome. Transplantation
. 2008; 85: 771–774.
73. McNeil K, Glanville AR, Wahlers T, et al. Comparison of mycophenolate mofetil and azathioprine for prevention of bronchiolitis obliterans syndrome in de novo lung transplant recipients. Transplantation
. 2006; 81: 998–1003.
74. Cai J, Terasaki PI. Induction immunosuppression improves long-term graft and patient outcome in organ transplantation: an analysis of United Network for Organ Sharing registry data. Transplantation
. 2010; 90: 1511–1515.
75. Christie JD, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: 29th adult lung and heart-lung transplant report—2012. J Heart Lung Transplant
. 2012; 31: 1073–1086.
76. Vos R, Vanaudenaerde BM, Ottevaere A, et al. Long-term azithromycin therapy for bronchiolitis obliterans syndrome: divide and conquer? J Heart Lung Transplant
. 2010; 29: 1358–1368.
77. Gottlieb J, Szangolies J, Koehnlein T, et al. Long-term azithromycin for bronchiolitis obliterans syndrome after lung transplantation. Transplantation
. 2008; 85: 36–41.
78. Jain R, Hachem RR, Morrell MR, et al. Azithromycin is associated with increased survival in lung transplant recipients with bronchiolitis obliterans syndrome. J Heart Lung Transplant
. 2010; 29: 531–537.
79. Vos R, Vanaudenaerde BM, Verleden SE, et al. A randomised controlled trial of azithromycin to prevent chronic rejection after lung transplantation. Eur Respir J
. 2011; 37: 164–172.
80. Verleden GM, Verleden SE, Vos R, et al. Montelukast for bronchiolitis obliterans syndrome after lung transplantation: a pilot study. Transpl Int
. 2011; 24: 651–656.
81. Zhou H, Latham CW, Zander DS, et al. Pirfenidone inhibits obliterative airway disease in mouse tracheal allografts. J Heart Lung Transplant
. 2005; 24: 1577–1585.
82. Morrell MR, Despotis GJ, Lublin DM, et al. The efficacy of photopheresis for bronchiolitis obliterans syndrome after lung transplantation. J Heart Lung Transplant
. 2010; 29: 424–431.
83. Benden C, Spelch R, Hofbauer GF, et al. Extracorporeal photopheresis after lung transplantation: a 10-year single-center experience. Transplantation
. 2008; 86: 1625–1627.
84. Greer M, Dierich M, De Wall C, et al. Phenotyping established chronic lung allograft dysfunction predicts extracorporeal photopheresis response in lung transplant patients. Am J Transplant
. 2013; 13: 911–918.
85. McKay C, Knight KA, Wright C. Beyond cancer treatment—a review of total lymphoid irradiation for heart and lung transplant recipients. J Med Rad Sci
. 2014; 61: 202.
86. Fisher AJ, Rutherford RM, Bozzino J, et al. The safety and efficacy of total lymphoid irradiation in progressive bronchiolitis obliterans syndrome after lung transplantation. Am J Transplant
. 2005; 5: 537–543.
87. Kawut SM, Lederer DJ, Keshavjee S, et al. Outcomes after lung retransplantation in the modern era. Am J Respir Crit Care Med
. 2008; 177: 114–120.
88. Sato M, Waddell TK, Wagnetz U, et al. Restrictive allograft syndrome (RAS): a novel form of chronic lung allograft dysfunction. J Heart Lung Transplant
. 2011; 30: 735–742.
89. Ofek E, Sato M, Saito T, et al. Restrictive allograft syndrome post lung transplantation is characterized by pleuroparenchymal fibroelastosis. Mod Pathol
. 2013; 26: 350–356.
90. Sato M, Hwang DM, Waddell TK, et al. Progression pattern of restrictive allograft syndrome after lung transplantation. J Heart Lung Transplant
. 2013; 32: 23–30.
91. Von der Thusen JH, Hansell DM, et al. Pleuroparenchymal fibroelastosis in patients with pulmonary disease secondary to bone marrow transplantation. Mod Pathol
. 2011; 24: 1633–1639.
92. Nakaseko C, Ozawa S, Sakaida E, et al. Incidence, risk factors and outcomes of bronchiolitis obliterans after allogeneic stem cell transplantation. Int J Hematol
. 2011; 93: 375–382.
93. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med
. 2006; 3541: 1813–1826.
94. Chien JW, Duncan S, Williams KM, et al. Bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation—an increasingly recognized manifestation of chronic graft-versus-host disease. Biol Blood Marrow Transplant
. 2010; 16: S106–S114.
95. Fujii N, Nakase K, Asakura S, et al. Bronchiolitis obliterans with allogeneic hematopoietic cell transplantation: a 10-year experience of the Okayama BMT Group. Int J Hematol
. 2014; 99: 644–651.
96. Vieira AG, Funke VAM, Nunes EC, et al. Bronchiolitis obliterans in patients undergoing allogeneic hematopoietic SCT. Bone Marrow Transplant
. 2014; 49: 812–817.
97. Forslöw U, Matson J, Gustafsson T, et al. Donor lymphocyte infusion may reduce the incidence of bronchiolitis obliterans after allogeneic stem cell transplantation. Biol Blood Marrow Transplant
. 2011; 17: 1214–1221.
98. Thomas LHS, Loberiza FR, Klein JP, et al. Risk factors for bronchiolitis obliterans in allogeneic hematopoietic stem-cell transplantation for leukemia. Chest
. 2005; 128: 153–161.
99. Dudek AZ, Mahaseth H, DeFor TE, et al. Bronchiolitis obliterans in chronic graft-versus-host disease: analysis of risk factors and treatment outcomes. Biol Blood Marrow Transplant
. 2003; 9: 657–666.
100. Williams KM, Chien JW, Gladwin MT, et al. Bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation. JAMA
. 2009; 302: 306–314.
101. Filipovich AH, Weisdorf D, Pavletic S, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant
. 2005; 11: 945–956.
102. Gazourian L, Rogers AJ, Ibanga R, et al. Factors associated with bronchiolitis obliterans syndrome and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation. Am J Hematol
. 2014; 89: 404–409.
103. Ringdén O, Remberger M, Ruutu T, et al. Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Nordic Bone Marrow Transplantation Group. Blood
. 1999; 93: 2196–2201.
104. Nakasone H, Kanda J, Yano S, et al. A case-control study of bronchiolitis obliterans syndrome following allogeneic hematopoietic stem cell transplantation. Transpl Int
. 2013; 26: 631–639.
105. Alam N, Marras TK, Atenafu EG, et al. Allogeneic peripheral blood stem cell transplantation significantly increases risk of chronic graft-versus-host disease of lung compared with bone marrow transplantation. Biol Blood Marrow Transplant
. 2012; 18: 1905–1910.
106. Ditschkowski A, Elmaagacli AH, Trenschel R, et al. T-cell depletion prevents from bronchiolitis obliterans and bronchiolitis obliterans with organizing pneumonia after allogeneic hematopoietic stem cell transplantation with related donors. Haematologica
. 2007; 92: 558–561.
107. Au BK, Au MA, Chien JW. Bronchiolitis obliterans syndrome epidemiology after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant
. 2011; 17: 1072–1078.
108. Thompson PA, Lim A, Panek-Hudson Y, et al. Screening with spirometry is a useful predictor of later development of noninfectious pulmonary syndromes in patients undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant
. 2014; 20: 781–786.
109. Ziakis PD, Zervou FN, Zacharioudakis IM, et al. Graft-versus-host-disease prophylaxis after transplantation: a network meta-analysis. PLoS One
. 2014; 9: e114735.
110. Dignan FL, Amrolia P, Clark A, et al. Diagnosis and management of chronic graft-versus-host disease. Br J Haematol
. 2012; 158: 46–61.
111. Wolff D, Gerbitz A, Ayuk F, et al. consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD. Biol Blood Marrow Transplant
. 2010; 16: 1611–1628.
112. Hildebrandt GC, Fazekas T, Lawitschka A, et al. Diagnosis and treatment of pulmonary chronic GVHD: report from the consensus conference on clinical practice in chronic GVHD. Bone Marrow Transplant
. 2011; 46: 1283–1295.
113. Bergeron A, Belle A, Chevret S, et al. Combined inhaled steroids and bronchodilatators in obstructive airway disease after allogeneic stem cell transplantation. Bone Marrow Transplant
. 2007; 39: 547–553.
114. Khalid M, Al SA, Saleemi S, et al. Azithromycin in bronchiolitis obliterans complicating bone marrow transplantation: a preliminary study. Eur Respir J
. 2005; 25: 490–493.
115. Lam DCL, Lam B, Wong MKY, et al. Effects of Azithromycin in bronchiolitis obliterans syndrome after hematopoietic SCT-a randomized double- blinded placebo-controlled study. Bone Marrow Transplant
. 2011; 46: 1551–1556.
116. Norman BC, Jacobsohn DA, Williams KM, et al. Fluticasone, azithromycin and montelukast therapy in reducing corticosteroid exposure in bronchiolitis obliterans syndrome after allogeneic hematopoietic SCT: a case series of eight patients. Bone Marrow Transplant
. 2011; 46: 1369–1373.
117. Busca A, Locatelli F, Marmont F, et al. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. Am J Hematol
. 2007; 82: 45–52.
118. Chiang KY, Abhyankar S, Bridges K, et al. Recombinant human tumor necrosis factor receptor fusion protein as complementary treatment for chronic graft-versus-host disease. Transplantation
. 2002; 73: 665–667.
119. Flowers ME, Apperley JF, van Besien K, et al. A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease. Blood
. 2008; 112: 2667–2674.
120. Couriel DR, Hosing C, Saliba R, et al. Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD. Blood
. 2006; 107: 3074–3080.
121. Messina C, Locatelli F, Lanino E, et al. Extracorporeal photochemotherapy for paediatric patients with graft-versus-host disease after haematopoietic stem cell transplantation. Br J Haematol
. 2003; 122: 118–127.
122. Rubegni P, Cuccia A, Sbano P, et al. Role of extracorporeal photochemotherapy in patients with refractory chronic graft-versus-host disease. Br J Haematol
. 2005; 130: 271–275.
123. Lucid CE, Savani BN, Engelhardt BG, et al. Extracorporeal photopheresis in patients with refractory bronchiolitis obliterans developing after allo-SCT. Bone Marrow Transplant
. 2011; 46: 426–429.
124. Olivieri A, Locatelli F, Zecca M, et al. Imatinib for refractory chronic graft-versus-host disease with fibrotic features. Blood
. 2009; 114: 709–718.
125. Zaja F, Bacigalupo A, Patriarca F, et al. Treatment of refractory chronic GVHD with rituximab: a GITMO study. Bone Marrow Transplant
. 2007; 40: 273–277.
126. Kim SJ, Lee JW, Jung CW, et al. Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II study. Haematologica
. 2010; 95: 1935–1942.
127. Kulkarni S, Powles R, Sirohi B, et al. Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease. Bone Marrow Transplant
. 2003; 32: 165–170.
128. Vogl UM, Nagayama K, Bojic M, et al. Lung transplantation for bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation: a single-center experience. Transplantation
. 2013; 95: 623–628.
129. Soubani AO, Kingah P, Alshabani K, et al. Lung transplantation following hematopoietic stem cell transplantation: report of two cases and systematic review of literature. Clin Transplant
. 2014; 28: 776–782.